McKinsey January 9, 2025
Ahsan Saeed, Gaurav Agrawal, Guang Yang, Stephan Wurzer, with Alana Horowitz, Daniel von Bornstädt, and Jan Günthner,

Leading companies are revamping research and early development to curb lengthy drug development timelines and rising costs.

The journey to bring new medicines to market remains long and costly, despite recent technological and process improvements in biopharma R&D. It takes about a decade, on average, from candidate nomination to launch, and study and application costs for investigational new drugs (INDs) have soared in recent years by 20–30 percent.

These challenges stem partly from the growing complexity of research and early development, fueled by an explosion of data and insights generated by experiments conducted across diverse therapeutic areas. To assess a drug candidate’s clinical potential, researchers need to efficiently analyze vast amounts of information, considering factors like structure, target binding, modulation...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech
FTC pauses PBM litigation in win for Caremark, Express Scripts, Optum Rx
Pharma Dodges The Tariff Bullet — But For How Long?
Noom, LillyDirect pharmacy provider partner to increase access to Zepbound
Robots can aid hospital pharmacies in safer and more sustainable cancer drug preparation
PBM Private Labeling Boosts Biosimilars, Raises Concerns

Share This Article